Extrusion-based bioprinting of alginate-gelatin hydrogel scaffolds shows promise for personalized wound healing, with optimized formulations (7% alginate-8% gelatin) demonstrating balanced printability, mechanical strength, and cell viability. Clinical translation requires navigation of complex regulatory pathways and standardization of manufacturing processes, though current evidence suggests biologic scaffolds can accelerate healing compared to standard care.
Extrusion-based bioprinting represents an emerging frontier in regenerative medicine, utilizing bioinks and biomaterial solutions to create three-dimensional constructs for tissue engineering applications [1]. The foundational work in this space has centered on optimizing hydrogel compositions, particularly alginate-gelatin blends, to achieve the critical balance between printability, mechanical performance, and biological functionality.
Recent systematic investigations have identified optimal alginate-gelatin formulations through rigorous experimental design. A landmark study proposes a blend of 7% alginate and 8% gelatin that yields high printability, mechanical strength and stiffness, and cell viability [5]. This formulation emerged from comprehensive rheological characterization and mechanical testing of sodium alginate-gelatin hydrogel blends, demonstrating the necessity of empirical optimization [2]. Complementary research utilizing orthogonal experimental design and grey relational analysis further refined printing parameters, establishing that hydrogel filament formability and die swell behavior are critical control variables [3].
Process parameters significantly impact scaffold quality and functionality. Optimization studies identified optimal flow rates of 10 ml/h with an 18% nozzle gauge and 4% alginate concentration as parameters supporting consistent filament deposition [4]. These findings underscore that material composition and extrusion parameters operate as interdependent variables requiring simultaneous optimization rather than sequential adjustment.
Beyond material chemistry, three-dimensional scaffold architecture profoundly influences therapeutic efficacy. Interconnected porosity and pore size represent critical design parameters impacting cellular behavior and tissue formation [6]. Scaffold design must account for multiple porosity-related factors including pore size geometry, distribution, and interconnectivity to facilitate cellular infiltration, nutrient diffusion, and tissue regeneration [10].
Intelligent scaffold design provides dynamic control over the microenvironment through multiple mechanisms. Smart biomaterials and scaffolds enable precise modulation of pore size, scaffold fibrous orientation, and varying stiffness gradients—architectural features that directly control cell migration, angiogenesis, and tissue organization [8]. This level of microenvironmental control positions bioprinted scaffolds as potentially superior to static biomaterial alternatives for complex wound healing applications.
Hybrid scaffold approaches incorporating multiple material phases represent an emerging strategic direction. Comprehensive analyses demonstrate that hybrid scaffolds—combining complementary materials—show broad applicability across cardiology, orthopedics, and neural tissue regeneration [7]. For wound healing specifically, these architecturally complex scaffolds can simultaneously address multiple healing phase requirements: hemostasis, inflammation regulation, angiogenesis, and extracellular matrix deposition.
Bioink formulation for cutaneous wound healing applications requires careful consideration of multiple functional requirements beyond printability. Extrusion-based bioprinting bioinks for wound healing applications must balance antimicrobial performance, biocompatibility, gas permeability, and absorption capacity [12]. Effective wound dressing functionality demands that bioinks exert maximal antimicrobial performance while maintaining cellular support and environmental permeability [12].
Biopolymer selection significantly influences wound healing outcomes. Chitosan—a biopolymer derived from chitin—demonstrates particular promise for wound applications due to its biodegradability, inherent antibacterial properties, and capacity to support cell growth [14]. Gel-based biomaterials enhance wound healing by providing sustained bioactive molecule release, improving cell growth, and facilitating tissue repair [15].
Advanced bioink formulations increasingly incorporate therapeutic payloads. Secretome-loaded 3D-printed hydrogels represent an innovative approach wherein bioprinted scaffolds serve as sustained-release vehicles for bioactive molecules derived from stem cell secretions or growth factor concentrates [15]. This integration of biological cargo within structural scaffolds creates combination products with enhanced regenerative potential compared to scaffold-alone approaches.
Clinical evidence for scaffold-based wound healing, though still developing, suggests meaningful therapeutic benefit. Research in diabetic foot ulcer (DFU) populations indicates that biologic scaffolds can accelerate healing compared with standard care [9]. However, available clinical evidence remains limited to case series and observational designs rather than large-scale randomized controlled trials [9], representing a significant evidence gap for clinical translation.
The therapeutic mechanisms supporting improved wound healing outcomes involve multiple biological pathways. Personalized bioprinting enables customization of scaffold architecture to individual wound geometry and tissue defect characteristics. This personalization potential addresses a critical limitation of off-the-shelf wound products: the biological and architectural heterogeneity of chronic wounds and tissue defects. Customized scaffolds can be engineered with patient-specific dimensions, pore architectures, and therapeutic payloads tailored to individual healing requirements.
Translation from laboratory development to clinical implementation requires navigation of complex regulatory frameworks. Bioprinted constructs classified as combination products—incorporating both structural biomaterial and biologic components—must satisfy FDA regulations for both medicinal products and medical devices [18]. This dual regulatory requirement creates considerable complexity, as developers must demonstrate safety and efficacy across multiple regulatory dimensions simultaneously.
Current regulatory challenges stem partly from standardization deficiencies in bioink manufacturing and characterization. Laboratories employ different quality standards and testing methodologies, impeding harmonization efforts [17]. The absence of standardized test methods creates barriers to regulatory acceptance and clinical scale-up [17]. Regulatory pathways remain nascent, with FDA guidance for three-dimensional bioprinting still evolving [20].
Scaling strategies for bioink manufacturing represent a critical bottleneck for clinical translation. Current manufacturing approaches optimized for research quantities must be adapted for clinical-scale production while maintaining product consistency, sterility, and functional performance. This transition from bench-scale to clinical-scale manufacturing requires substantial process development and regulatory documentation [17].
The field of extrusion-based bioprinting for personalized wound healing stands at an inflection point. Material science advances have established optimal alginate-gelatin formulations with demonstrated printability, mechanical performance, and biological activity. Scaffold architectural principles enabling control of porosity, stiffness gradients, and cellular guidance are well-established. Bioink innovations incorporating therapeutic payloads and antimicrobial functionality address functional requirements beyond structural support. Clinical evidence, though limited, suggests meaningful healing benefits compared to standard care.
Remaining barriers to widespread clinical adoption involve regulatory harmonization, manufacturing standardization, and expanded clinical evidence generation. The field requires coordinated effort toward standardized characterization methods, regulatory guidance clarification, and adequately powered clinical trials demonstrating safety and efficacy in diverse wound populations. Successful translation of this promising technology depends on bridging the current gap between materials science innovation and clinical implementation infrastructure.
Personalized bioprinting of hydrogel scaffolds represents a rational therapeutic approach to chronic wound management, combining patient-specific customization with materials engineered for biological performance. Continued refinement of formulations, printing parameters, and regulatory pathways should accelerate clinical adoption and establish this technology as a transformative approach to challenging wound healing problems.